Fig. 2From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world studyKaplan–Meier analyses of progression-free survival according to A α-fetoprotein levels, B tumor size, C regorafenib dose, and D best responseBack to article page